NTRA
$195.28-7.45 (-3.67%)
Natera, Inc., a diagnostics company, provides molecular testing services worldwide.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier scr...
Recent News
1 Unprofitable Stock to Own for Decades and 2 Facing Headwinds
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
1 Cash-Heavy Stock to Target This Week and 2 We Question
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
A Look At Natera (NTRA) Valuation After New Signatera Data And Zenith Genomics Launch
Natera (NTRA) is back in focus after publishing new peer reviewed data on its Signatera cancer assay and rolling out the Zenith genomics rare disease platform. These developments sharpen attention on the stock’s recent performance. See our latest analysis for Natera. The latest Signatera data and Zenith launch have come alongside a 1-day share price return of 5.23% to US$197.68. This comes even as the 30-day share price return is 4.15% lower and the 1-year total shareholder return stands at...
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries.
3 Growth Stocks to Add to Your Roster
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.